Related Experiment Video
Updated: Jun 23, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Front-line treatment in younger patients with multiple myeloma
S Vincent Rajkumar1, Pieter Sonneveld
1Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. rajkumar.vincent@mayo.edu
Abstract:
The treatment of newly diagnosed myeloma has evolved rapidly. The choice of initial therapy depends on eligibility for stem cell transplantation, as well as baseline risk factors. Eligibility for transplantation is important since the choice of initial therapy is primarily melphalan-based in patients who are not candidates for transplant, while melphalan-containing regimens are avoided as induction therapy in transplant candidates. An assessment of risk based on independent prognostic markers is important mainly for prognosis but may have some value in choice of initial therapy. For example, bortezomib-based regimens may have particular value in patients with certain high-risk features. This review discusses the current status of front-line therapy in younger patients with myeloma who are candidates for stem cell transplantation.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Differentiation of Common Myeloid Progenitor Cells